Glenview Trust Co bought a new stake in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 157,895 shares of the company’s stock, valued at approximately $18,192,000. Johnson & Johnson comprises approximately 0.5% of Glenview Trust Co’s holdings, making the stock its 16th largest position.
A number of other hedge funds also recently added to or reduced their stakes in JNJ. New England Research & Management Inc. boosted its stake in shares of Johnson & Johnson by 20.0% in the third quarter. New England Research & Management Inc. now owns 30,343 shares of the company’s stock valued at $3,584,000 after buying an additional 5,063 shares during the last quarter. Hefty Wealth Partners boosted its stake in shares of Johnson & Johnson by 559.4% in the third quarter. Hefty Wealth Partners now owns 1,121 shares of the company’s stock valued at $132,000 after buying an additional 951 shares during the last quarter. Franklin Street Advisors Inc. NC boosted its stake in shares of Johnson & Johnson by 31.0% in the third quarter. Franklin Street Advisors Inc. NC now owns 84,373 shares of the company’s stock valued at $9,967,000 after buying an additional 19,947 shares during the last quarter. Stillwater Investment Management LLC boosted its stake in shares of Johnson & Johnson by 4.2% in the third quarter. Stillwater Investment Management LLC now owns 33,863 shares of the company’s stock valued at $4,000,000 after buying an additional 1,355 shares during the last quarter. Finally, Monarch Capital Management Inc. boosted its stake in shares of Johnson & Johnson by 0.4% in the third quarter. Monarch Capital Management Inc. now owns 70,556 shares of the company’s stock valued at $8,335,000 after buying an additional 307 shares during the last quarter. 65.30% of the stock is currently owned by institutional investors.
Shares of Johnson & Johnson (NYSE:JNJ) traded down 0.09% on Friday, reaching $121.76. 6,021,721 shares of the company’s stock traded hands. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $129.00. The stock has a market capitalization of $330.38 billion, a price-to-earnings ratio of 20.53 and a beta of 0.74. The stock’s 50-day moving average price is $125.17 and its 200-day moving average price is $118.12.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/04/22/glenview-trust-co-buys-shares-of-157895-johnson-johnson-jnj.html.
Several equities analysts recently issued reports on JNJ shares. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Tuesday, January 3rd. Jefferies Group LLC reiterated a “hold” rating and issued a $110.00 target price (up from $107.00) on shares of Johnson & Johnson in a research note on Thursday, January 5th. Royal Bank of Canada reiterated a “buy” rating and issued a $133.00 target price on shares of Johnson & Johnson in a research note on Friday, January 6th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $121.63 price objective for the company in a research report on Monday, January 9th. Finally, Goldman Sachs Group Inc reduced their price objective on shares of Johnson & Johnson from $120.00 to $115.00 and set a “neutral” rating for the company in a research report on Wednesday, January 25th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and an average price target of $125.53.
In other news, VP Paulus Stoffels sold 22,000 shares of the stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $117.29, for a total transaction of $2,580,380.00. Following the transaction, the vice president now owns 127,650 shares of the company’s stock, valued at approximately $14,972,068.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.11% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
